Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SKAN Group AG ( (CH:SKAN) ) has provided an announcement.
SKAN Group AG announced provisional, unaudited figures for its 2025 financial year, indicating a decline in net sales to around CHF 332 million from CHF 361.3 million in 2024 and a sharper drop in EBITDA to approximately CHF 38 million from CHF 57.0 million, while order intake slightly increased to around CHF 365 million from CHF 359.5 million. The detailed 2025 annual results and accompanying annual report will be published on 24 March 2026, when management is also set to brief investors, analysts and media in Zurich, giving stakeholders further insight into the drivers of the weaker profitability against a stable demand backdrop.
The most recent analyst rating on (CH:SKAN) stock is a Sell with a CHF58.00 price target. To see the full list of analyst forecasts on SKAN Group AG stock, see the CH:SKAN Stock Forecast page.
More about SKAN Group AG
SKAN Group AG is a pioneer and global market and technology leader in high-quality isolator systems for aseptic and aseptic-toxic production processes in the (bio-)pharmaceutical industry. Its isolators are used for sterile drug filling and are complemented by process support, services and consumables, serving pharmaceutical and biotech companies, contract manufacturers and research laboratories worldwide. Founded in 1968 and headquartered in Allschwil near Basel, the company employs around 1,700 people across sites in Europe, the US, Japan and Brazil.
Average Trading Volume: 36,939
Technical Sentiment Signal: Hold
Current Market Cap: CHF1.38B
For a thorough assessment of SKAN stock, go to TipRanks’ Stock Analysis page.